Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners.
Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AG-270, including any unresolved nausea, vomiting, or diarrhea that is National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >1.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of venetoclax
Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow
Gastrointestinal (GI) function or disease that may significantly alter the absorption of the study drugs
Patient is unable to swallow oral medications or has impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption (including, but not limited to active inflammatory bowel disease, malabsorption syndrome); concomitant therapy with antacids and anti-emetics is permissible
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of GI function or GI disease that may significantly alter the absorption of INC280
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL161 as per physicians opinion
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Patients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of quizartinib.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral vemurafenib
Impairment of GI function
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) grade > 1
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the swallowing absorption of panobinostat and MLN9708
Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib
Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin; patients with gastric bypass surgery are excluded
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-5829, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 1
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-5829, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 1
Patients with known severe impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib
Impairment of gastrointestinal (GI) function
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ceritinib or LEE011
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Patients with a known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL161
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PANOBINOSTAT or RUXOLITINIB
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of gastrointestinal (GI) function or GI disease that might significantly alter the absorption of study drug
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease
NON-PROGRESSED DIPG (STRATUM 2): Patients have impairment of GI function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease
Impairment of GI function or GI disease that may significantly alter the absorption of ceritinib
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LBH589
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
Impairment of GI function or GI disease that may significantly alter the absorption of panobinostat.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral WNT974/LGX818
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of GI function or GI disease that could interfere with the absorption of AEB071 or everolimus.
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of gastro-intestinal (GI) function or GI disease that may significantly alter the absorption of LEE011 such as patients with a history of GI surgery which may result in intestinal blind loops and patients with clinically significant gastroparesis, unresolved nausea, vomiting, or diarrhea of CTCAE grade > 1
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
Impairment of GI function or GI disease that may significantly alter the absorption of LBH589
Impaired gastrointestinal function (GI) or GI disease that may significantly alter the absorption of oral medications
History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of LAM-002A
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral Everolimus;
